NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Bayer says needs more time for Monsanto deal approval

Published 19/09/2017, 16:26
© Reuters. The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal
BAYGN
-
MON
-

By Ludwig Burger

MONHEIM, Germany (Reuters) - German drugs and pesticides group Bayer (DE:BAYGn) said on Tuesday it was now likely to be early next year before it can complete its $66 billion (£48.89 billion) deal to acquire U.S. group Monsanto (N:MON), later than previously expected.

The European Commission has been scrutinising the proposed takeover with a deadline of Jan. 8 but Bayer said in a statement it had asked the regulator for an extension on the investigation to Jan. 22, to which the EU Commission responded by saying it would take a decision shortly.

Liam Condon, head of Bayer's Crop Science division, said: "An anticipated closing of the deal in early 2018 is now more likely than end of 2017." He also expressed his confidence that the EU would give the green light.

However, the company said it could not think of any asset sales which could be made to allay the European Commission's concerns about what it sees as Bayer's looming dominance in digital farming.

The Commission last month started an in-depth investigation of the takeover, saying it was worried about competition in various pesticide and seeds markets.

Among a slew of markets where competition was at risk, the EU Commission at the time named Monsanto's weed killer glyphosate, or Roundup, which competes with Bayer's glufosinate; vegetable and canola seeds; and licensing of cotton-seed technology to peers.

More broadly, it said the deal might slow the race to develop new products, and that the European Union would try to prevent Bayer from becoming too dominant in combined offerings of seeds and pesticides with the help of digital farming tools such as connected sensors, software and precision machines.

Bayer, which was making a media presentation on its Crop Science business on Tuesday, also said the division would face volatile global markets for the rest of the year but would slowly return to growth from 2018, including its embattled Brazilian business.

© Reuters. The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal

Bayer warned in June that poor sales at crop protection distributors in Brazil would full-year hit earnings.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.